Septerna Inc
SEPN15.940USD
+1.550+10.77%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
710.41MMarket Cap
LossP/E TTM
More Details of Septerna Inc Company
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. It is focused in major therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
Company Info
Ticker SymbolSEPN
Company nameSepterna Inc
IPO dateOct 25, 2024
CEODr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Number of employees75
Security typeOrdinary Share
Fiscal year-endOct 25
Address250 East Grand Avenue, Suite 65
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94080
Phone16503383533
Websitehttps://septerna.com/
Ticker SymbolSEPN
IPO dateOct 25, 2024
CEODr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
826.91K
-12.75%
Dr. Uwe Klein, Ph.D.
Dr. Uwe Klein, Ph.D.
Senior Vice President - Biological Sciences
Senior Vice President - Biological Sciences
135.66K
+20.42%
Dr. Alan Ezekowitz, M.D., Ph.D.
Dr. Alan Ezekowitz, M.D., Ph.D.
Director
Director
117.42K
-22.44%
Mr. Daniel (Dan) Long
Mr. Daniel (Dan) Long
Senior Vice President - Drug Discovery
Senior Vice President - Drug Discovery
101.04K
--
Ms. Samira Shaikhly
Ms. Samira Shaikhly
Chief People Officer
Chief People Officer
36.81K
--
Mr. Gil Labrucherie
Mr. Gil Labrucherie
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
--
--
Mr. Abraham (Abe) Bassan
Mr. Abraham (Abe) Bassan
Independent Director
Independent Director
--
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
--
-100.00%
Dr. Bernard J. Coulie, M.D., Ph.D.
Dr. Bernard J. Coulie, M.D., Ph.D.
Independent Director
Independent Director
--
-100.00%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Dr. Jeffrey (Jeff) Finer, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
826.91K
-12.75%
Dr. Uwe Klein, Ph.D.
Dr. Uwe Klein, Ph.D.
Senior Vice President - Biological Sciences
Senior Vice President - Biological Sciences
135.66K
+20.42%
Dr. Alan Ezekowitz, M.D., Ph.D.
Dr. Alan Ezekowitz, M.D., Ph.D.
Director
Director
117.42K
-22.44%
Mr. Daniel (Dan) Long
Mr. Daniel (Dan) Long
Senior Vice President - Drug Discovery
Senior Vice President - Drug Discovery
101.04K
--
Ms. Samira Shaikhly
Ms. Samira Shaikhly
Chief People Officer
Chief People Officer
36.81K
--
Mr. Gil Labrucherie
Mr. Gil Labrucherie
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Aug 20
Updated: Wed, Aug 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
23.39%
RA Capital Management, LP
15.69%
Driehaus Capital Management, LLC
10.50%
BVF Partners L.P.
9.86%
Samsara BioCapital, LLC
7.06%
Other
33.50%
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
23.39%
RA Capital Management, LP
15.69%
Driehaus Capital Management, LLC
10.50%
BVF Partners L.P.
9.86%
Samsara BioCapital, LLC
7.06%
Other
33.50%
Shareholder Types
Shareholders
Proportion
Venture Capital
48.31%
Investment Advisor/Hedge Fund
16.82%
Hedge Fund
16.05%
Investment Advisor
14.37%
Research Firm
3.64%
Individual Investor
2.94%
Private Equity
1.21%
Bank and Trust
0.06%
Insurance Company
0.02%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
140
48.42M
108.66%
+736.53K
2025Q1
139
54.98M
123.75%
+8.24M
2024Q4
107
54.00M
121.73%
+28.70M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Third Rock Ventures, LLC
10.43M
23.4%
+18.86K
+0.18%
Mar 31, 2025
RA Capital Management, LP
7.00M
15.7%
--
--
Mar 31, 2025
Driehaus Capital Management, LLC
4.66M
10.46%
+1.54M
+49.23%
May 31, 2025
BVF Partners L.P.
4.40M
9.87%
+1.94M
+79.29%
Mar 31, 2025
Samsara BioCapital, LLC
3.15M
7.07%
+380.61K
+13.75%
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.20M
4.94%
--
--
Mar 31, 2025
Goldman Sachs & Company, Inc.
1.45M
3.25%
-224.96K
-13.44%
Mar 31, 2025
The Vanguard Group, Inc.
995.04K
2.23%
+10.01K
+1.02%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.16M
2.61%
-78.59K
-6.33%
Mar 31, 2025
Avoro Capital Advisors LLC
1.34M
3%
+227.50K
+20.50%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
ProShares Hedge Replication ETF
0.01%
Fidelity MSCI Health Care Index ETF
0%
iShares Health Innovation Active ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
Proportion0.01%
Fidelity MSCI Health Care Index ETF
Proportion0%
iShares Health Innovation Active ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
